scout

Ian Flinn, MD, PhD, Sarah Cannon Research Institute

Articles by Ian Flinn, MD, PhD, Sarah Cannon Research Institute

Case Discussion: 68-Year-Old With R/R Follicular Lymphoma

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

R/R Follicular Lymphoma: Testing for EZH2

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

EZH2 Inhibition in R/R FL: Safety & Efficacy Data

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Tazemetostat for R/R Follicular Lymphoma

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

PI3K Inhibitors for R/R Follicular Lymphoma

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

R/R Follicular Lymphoma: Third-Line Treatment Options

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.

Transplantation for R/R Follicular Lymphoma

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.

MRD Testing in R/R Follicular Lymphoma

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.

Role of Rebiopsy in R/R Follicular Lymphoma

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute

The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.

Latest Updated Articles